Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study
Abstract The standard treatment for adult acute lymphoblastic leukemia (ALL) is undefined. Patients with newly diagnosed standard-risk ALL at a single institution were retrospectively analyzed. From 2010 to 2017, 46 patients were treated using the modified Berlin–Frankfurt–Münster (BFM)-ALL-95 regimen. Hematologic and molecular complete remission (CR) rates of 91.3% and 76.1% were achieved. The 5-year event-free survival (EFS) and overall survival (OS) rates for all patients in the cohort were 58.0% (95% confidence interval, 42.1–73.9%) and 66.7% (95% CI, 51.4–82.0%), respectively. No patient presented with central nervous system involvement after CR in this study. This condition could be related to four doses of high-dose methotrexate (MTX) every 3 months during the maintenance phase. Multivariate analysis revealed that minimal residual disease positive and time interval between induction IA and Protocol M of more than 70 days were independent adverse factors for EFS and OS. One or more instances of grade 4 myelosuppression occurred during induction therapy. Nonhematological side effects were mild. No toxicity-related deaths were observed in the entire cohort. The data indicated that the modified regimen is well tolerated and can produce the promising outcomes in Chinese adults with standard-risk ALL..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
International journal of hematology - 110(2019), 4 vom: 18. Juli, Seite 458-465 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Chun [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Acute lymphoblastic leukemia |
|---|
| Anmerkungen: |
© Japanese Society of Hematology 2019 |
|---|
| doi: |
10.1007/s12185-019-02703-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR025128531 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR025128531 | ||
| 003 | DE-627 | ||
| 005 | 20230519221450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-019-02703-0 |2 doi | |
| 035 | |a (DE-627)SPR025128531 | ||
| 035 | |a (SPR)s12185-019-02703-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Chun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Japanese Society of Hematology 2019 | ||
| 520 | |a Abstract The standard treatment for adult acute lymphoblastic leukemia (ALL) is undefined. Patients with newly diagnosed standard-risk ALL at a single institution were retrospectively analyzed. From 2010 to 2017, 46 patients were treated using the modified Berlin–Frankfurt–Münster (BFM)-ALL-95 regimen. Hematologic and molecular complete remission (CR) rates of 91.3% and 76.1% were achieved. The 5-year event-free survival (EFS) and overall survival (OS) rates for all patients in the cohort were 58.0% (95% confidence interval, 42.1–73.9%) and 66.7% (95% CI, 51.4–82.0%), respectively. No patient presented with central nervous system involvement after CR in this study. This condition could be related to four doses of high-dose methotrexate (MTX) every 3 months during the maintenance phase. Multivariate analysis revealed that minimal residual disease positive and time interval between induction IA and Protocol M of more than 70 days were independent adverse factors for EFS and OS. One or more instances of grade 4 myelosuppression occurred during induction therapy. Nonhematological side effects were mild. No toxicity-related deaths were observed in the entire cohort. The data indicated that the modified regimen is well tolerated and can produce the promising outcomes in Chinese adults with standard-risk ALL. | ||
| 650 | 4 | |a Acute lymphoblastic leukemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adults |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Standard-risk |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Modified BFM-95 regimen |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cai, Xiuyu |4 aut | |
| 700 | 1 | |a Chen, Xiaoqin |4 aut | |
| 700 | 1 | |a Liang, Yang |4 aut | |
| 700 | 1 | |a Xia, Zhongjun |4 aut | |
| 700 | 1 | |a Wang, Hua |0 (orcid)0000-0002-9751-8847 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Tokyo [u.a.] : Springer, 1995 |g 110(2019), 4 vom: 18. Juli, Seite 458-465 |w (DE-627)SPR025085697 |w (DE-600)2028991-1 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2019 |g number:4 |g day:18 |g month:07 |g pages:458-465 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12185-019-02703-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2019 |e 4 |b 18 |c 07 |h 458-465 | ||